Lee Hambright
Stock Analyst at Bernstein
(4.29)
# 468
Out of 4,667 analysts
22
Total ratings
75%
Success rate
10.56%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Outperform | $96 → $97 | $84.20 | +15.20% | 2 | Nov 20, 2024 | |
| PODD Insulet | Initiates: Outperform | $300 | $266.58 | +12.54% | 1 | Nov 6, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Outperform | $42 | $30.15 | +39.30% | 1 | Nov 6, 2024 | |
| DXCM DexCom | Maintains: Outperform | $82 → $86 | $75.24 | +14.30% | 2 | Oct 25, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $92 → $100 | $90.49 | +10.52% | 1 | Oct 24, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $133 → $138 | $115.93 | +19.04% | 2 | Oct 17, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $350 → $365 | $541.82 | -32.63% | 2 | May 31, 2023 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $136 → $152 | $109.27 | +39.10% | 1 | May 3, 2023 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $183 | $153.52 | +19.20% | 4 | Mar 16, 2022 | |
| SYK Stryker | Upgrades: Outperform | $288 → $295 | $387.08 | -23.79% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $69.80 | +93.42% | 3 | Mar 16, 2022 |
Medtronic
Nov 20, 2024
Maintains: Outperform
Price Target: $96 → $97
Current: $84.20
Upside: +15.20%
Insulet
Nov 6, 2024
Initiates: Outperform
Price Target: $300
Current: $266.58
Upside: +12.54%
Tandem Diabetes Care
Nov 6, 2024
Initiates: Outperform
Price Target: $42
Current: $30.15
Upside: +39.30%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $82 → $86
Current: $75.24
Upside: +14.30%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $90.49
Upside: +10.52%
Abbott Laboratories
Oct 17, 2024
Maintains: Outperform
Price Target: $133 → $138
Current: $115.93
Upside: +19.04%
Intuitive Surgical
May 31, 2023
Maintains: Outperform
Price Target: $350 → $365
Current: $541.82
Upside: -32.63%
Zimmer Biomet Holdings
May 3, 2023
Maintains: Market Perform
Price Target: $136 → $152
Current: $109.27
Upside: +39.10%
Johnson & Johnson
Mar 16, 2022
Downgrades: Market Perform
Price Target: $183
Current: $153.52
Upside: +19.20%
Stryker
Mar 16, 2022
Upgrades: Outperform
Price Target: $288 → $295
Current: $387.08
Upside: -23.79%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $69.80
Upside: +93.42%